Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBITDA (2016 - 2025)

Historic EBITDA for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.5 million.

  • Arrowhead Pharmaceuticals' EBITDA rose 11620.76% to $28.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $236.1 million, marking a year-over-year increase of 13665.89%. This contributed to the annual value of $31.8 million for FY2025, which is 10528.6% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its EBITDA stood at $28.5 million for Q4 2025, which was up 11620.76% from $17.2 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBITDA peaked at $368.1 million during Q1 2025, and registered a low of -$177.7 million during Q2 2025.
  • For the 5-year period, Arrowhead Pharmaceuticals' EBITDA averaged around -$52.5 million, with its median value being -$67.8 million (2021).
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' EBITDA plummeted by 36645.1% in 2024 and then skyrocketed by 39022.99% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' EBITDA (Quarter) stood at -$62.9 million in 2021, then soared by 33.35% to -$41.9 million in 2022, then crashed by 218.15% to -$133.4 million in 2023, then tumbled by 31.8% to -$175.8 million in 2024, then surged by 116.21% to $28.5 million in 2025.
  • Its EBITDA was $28.5 million in Q4 2025, compared to $17.2 million in Q3 2025 and -$177.7 million in Q2 2025.